Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Merck KGaA

Diversification Gains Momentum As Companies Look To Derisk China

Quietly but unambiguously, pharma firms are accelerating their diversification away from China and are now looking to other emerging markets for growth, a strategy that reflects increasing pressures from China's volume-based procurement scheme but also US-China tensions and other geopolitical risks.

China Commercial

Digital Health Roundup: US FDA’s ‘Idea Lab’; Philips’ Roy Jakobs On AI Draft Framework; Apple Watch

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights key interviews with Philips’ CEO Roy Jakobs on NAM’s framework on AI, BD’s CTO Beth McCombs R&D initiatives and HSS spine co-chair Sheeraz Qureshi on his vision for integrating AI tech. Hannah Daniel discusses the FDA’s new initiative to create an idea lab for medical device use at home and a new feature on the Apple Watch to help people with Parkinson's disease overcome freezing gait.   

Digital Health Approvals

AstraZeneca’s Hot Streak Whets Investor Appetite For What’s Next

Outstanding Q1 growth in sales and profits have pleased the markets, and investors are now keen to hear more about AstraZeneca’s 2030 masterplan at its investor day next month.

Commercial Companies

IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf

Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.

Research & Development Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Pharmaceuticals
    • Drug Delivery
    • Nutraceuticals
  • Biotechnology
    • Synthesis Technologies, Production Processes
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Acadiana Ventures Inc.
    • Allergopharma Joachim Ganzer KG
    • AmpTec GmbH
    • Asceneuron
    • Chord Therapeutics SA
    • EMD Pharmaceuticals
    • Grzybowski Scientific Inventions (GSI)
    • Intermolecular Inc
    • JRH Biosciences
    • Merck Hoei Ltd.
    • Millipore
    • MilliporeSigma
    • Ormet Circuts Inc.
    • Serono
    • EMD Serono, Inc.
    • Sigma-Aldrich
    • Versum Materials, Inc.
UsernamePublicRestriction

Register